Financhill
Sell
12

ACIU Quote, Financials, Valuation and Earnings

Last price:
$2.30
Seasonality move :
2.44%
Day range:
$2.27 - $2.36
52-week range:
$2.19 - $4.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.82x
Volume:
142.2K
Avg. volume:
216.4K
1-year change:
-31.23%
Market cap:
$226.6M
Revenue:
$31M
EPS (TTM):
-$0.58

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ACIU
AC Immune SA
$820.9K -$0.21 -95.08% -273.39% $10.08
ADXN
Addex Therapeutics
$177.2K -- 2.35% -- $30.00
CRSP
CRISPR Therapeutics AG
$7.3M -$1.19 -96.36% -11.56% $83.60
MLTX
MoonLake Immunotherapeutics
-- -$0.59 -- -247.27% $78.67
MOLN
Molecular Partners AG
-- -$0.45 -100% -8.38% $10.78
NLSP
NLS Pharmaceutics
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ACIU
AC Immune SA
$2.29 $10.08 $226.6M -- $0.00 0% --
ADXN
Addex Therapeutics
$7.54 $30.00 $8.1M -- $0.00 0% 13.93x
CRSP
CRISPR Therapeutics AG
$42.12 $83.60 $3.6B -- $0.00 0% --
MLTX
MoonLake Immunotherapeutics
$38.67 $78.67 $2.4B -- $0.00 0% --
MOLN
Molecular Partners AG
$4.33 $10.78 $159.7M -- $0.00 0% 21.67x
NLSP
NLS Pharmaceutics
$1.58 -- $6M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ACIU
AC Immune SA
-- 5.657 -- 1.66x
ADXN
Addex Therapeutics
-- 3.522 -- 4.36x
CRSP
CRISPR Therapeutics AG
-- 2.038 -- 21.97x
MLTX
MoonLake Immunotherapeutics
-- 2.430 -- --
MOLN
Molecular Partners AG
-- 3.153 -- 14.08x
NLSP
NLS Pharmaceutics
-- 3.791 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ACIU
AC Immune SA
-- -$21.2M -37.26% -37.26% -1386.46% $5.4M
ADXN
Addex Therapeutics
-- -$719.5K 91.08% 91.08% -2836.3% -$713.3K
CRSP
CRISPR Therapeutics AG
$35M -$64.6M -18.65% -18.65% -184.54% -$50.3M
MLTX
MoonLake Immunotherapeutics
-- -$49.6M -- -- -- -$48.6M
MOLN
Molecular Partners AG
-- -$16.8M -37.36% -37.36% -2407.93% -$14.2M
NLSP
NLS Pharmaceutics
-- -- -- -- -- --

AC Immune SA vs. Competitors

  • Which has Higher Returns ACIU or ADXN?

    Addex Therapeutics has a net margin of -1389.36% compared to AC Immune SA's net margin of -2841.85%. AC Immune SA's return on equity of -37.26% beat Addex Therapeutics's return on equity of 91.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    ACIU
    AC Immune SA
    -- -$0.18 $124.3M
    ADXN
    Addex Therapeutics
    -- -$2.78 $13.1M
  • What do Analysts Say About ACIU or ADXN?

    AC Immune SA has a consensus price target of $10.08, signalling upside risk potential of 340.11%. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 297.88%. Given that AC Immune SA has higher upside potential than Addex Therapeutics, analysts believe AC Immune SA is more attractive than Addex Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACIU
    AC Immune SA
    3 0 0
    ADXN
    Addex Therapeutics
    0 0 0
  • Is ACIU or ADXN More Risky?

    AC Immune SA has a beta of 1.226, which suggesting that the stock is 22.632% more volatile than S&P 500. In comparison Addex Therapeutics has a beta of 1.757, suggesting its more volatile than the S&P 500 by 75.723%.

  • Which is a Better Dividend Stock ACIU or ADXN?

    AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACIU or ADXN?

    AC Immune SA quarterly revenues are $1.3M, which are larger than Addex Therapeutics quarterly revenues of $62.3K. AC Immune SA's net income of -$18M is lower than Addex Therapeutics's net income of -$1.8M. Notably, AC Immune SA's price-to-earnings ratio is -- while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is -- versus 13.93x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACIU
    AC Immune SA
    -- -- $1.3M -$18M
    ADXN
    Addex Therapeutics
    13.93x -- $62.3K -$1.8M
  • Which has Higher Returns ACIU or CRSP?

    CRISPR Therapeutics AG has a net margin of -1389.36% compared to AC Immune SA's net margin of -106.6%. AC Immune SA's return on equity of -37.26% beat CRISPR Therapeutics AG's return on equity of -18.65%.

    Company Gross Margin Earnings Per Share Invested Capital
    ACIU
    AC Immune SA
    -- -$0.18 $124.3M
    CRSP
    CRISPR Therapeutics AG
    -- -$0.44 $1.9B
  • What do Analysts Say About ACIU or CRSP?

    AC Immune SA has a consensus price target of $10.08, signalling upside risk potential of 340.11%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $83.60 which suggests that it could grow by 98.48%. Given that AC Immune SA has higher upside potential than CRISPR Therapeutics AG, analysts believe AC Immune SA is more attractive than CRISPR Therapeutics AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACIU
    AC Immune SA
    3 0 0
    CRSP
    CRISPR Therapeutics AG
    12 11 1
  • Is ACIU or CRSP More Risky?

    AC Immune SA has a beta of 1.226, which suggesting that the stock is 22.632% more volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.767, suggesting its more volatile than the S&P 500 by 76.677%.

  • Which is a Better Dividend Stock ACIU or CRSP?

    AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACIU or CRSP?

    AC Immune SA quarterly revenues are $1.3M, which are smaller than CRISPR Therapeutics AG quarterly revenues of $35M. AC Immune SA's net income of -$18M is higher than CRISPR Therapeutics AG's net income of -$37.3M. Notably, AC Immune SA's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is -- versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACIU
    AC Immune SA
    -- -- $1.3M -$18M
    CRSP
    CRISPR Therapeutics AG
    -- -- $35M -$37.3M
  • Which has Higher Returns ACIU or MLTX?

    MoonLake Immunotherapeutics has a net margin of -1389.36% compared to AC Immune SA's net margin of --. AC Immune SA's return on equity of -37.26% beat MoonLake Immunotherapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ACIU
    AC Immune SA
    -- -$0.18 $124.3M
    MLTX
    MoonLake Immunotherapeutics
    -- -$0.72 --
  • What do Analysts Say About ACIU or MLTX?

    AC Immune SA has a consensus price target of $10.08, signalling upside risk potential of 340.11%. On the other hand MoonLake Immunotherapeutics has an analysts' consensus of $78.67 which suggests that it could grow by 103.43%. Given that AC Immune SA has higher upside potential than MoonLake Immunotherapeutics, analysts believe AC Immune SA is more attractive than MoonLake Immunotherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACIU
    AC Immune SA
    3 0 0
    MLTX
    MoonLake Immunotherapeutics
    11 1 0
  • Is ACIU or MLTX More Risky?

    AC Immune SA has a beta of 1.226, which suggesting that the stock is 22.632% more volatile than S&P 500. In comparison MoonLake Immunotherapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ACIU or MLTX?

    AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MoonLake Immunotherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. MoonLake Immunotherapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACIU or MLTX?

    AC Immune SA quarterly revenues are $1.3M, which are larger than MoonLake Immunotherapeutics quarterly revenues of --. AC Immune SA's net income of -$18M is higher than MoonLake Immunotherapeutics's net income of -$45.6M. Notably, AC Immune SA's price-to-earnings ratio is -- while MoonLake Immunotherapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is -- versus -- for MoonLake Immunotherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACIU
    AC Immune SA
    -- -- $1.3M -$18M
    MLTX
    MoonLake Immunotherapeutics
    -- -- -- -$45.6M
  • Which has Higher Returns ACIU or MOLN?

    Molecular Partners AG has a net margin of -1389.36% compared to AC Immune SA's net margin of -2408.81%. AC Immune SA's return on equity of -37.26% beat Molecular Partners AG's return on equity of -37.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    ACIU
    AC Immune SA
    -- -$0.18 $124.3M
    MOLN
    Molecular Partners AG
    -- -$0.34 $165M
  • What do Analysts Say About ACIU or MOLN?

    AC Immune SA has a consensus price target of $10.08, signalling upside risk potential of 340.11%. On the other hand Molecular Partners AG has an analysts' consensus of $10.78 which suggests that it could grow by 148.97%. Given that AC Immune SA has higher upside potential than Molecular Partners AG, analysts believe AC Immune SA is more attractive than Molecular Partners AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACIU
    AC Immune SA
    3 0 0
    MOLN
    Molecular Partners AG
    3 1 0
  • Is ACIU or MOLN More Risky?

    AC Immune SA has a beta of 1.226, which suggesting that the stock is 22.632% more volatile than S&P 500. In comparison Molecular Partners AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ACIU or MOLN?

    AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molecular Partners AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. Molecular Partners AG pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACIU or MOLN?

    AC Immune SA quarterly revenues are $1.3M, which are larger than Molecular Partners AG quarterly revenues of $787.5K. AC Immune SA's net income of -$18M is lower than Molecular Partners AG's net income of -$12.8M. Notably, AC Immune SA's price-to-earnings ratio is -- while Molecular Partners AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is -- versus 21.67x for Molecular Partners AG. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACIU
    AC Immune SA
    -- -- $1.3M -$18M
    MOLN
    Molecular Partners AG
    21.67x -- $787.5K -$12.8M
  • Which has Higher Returns ACIU or NLSP?

    NLS Pharmaceutics has a net margin of -1389.36% compared to AC Immune SA's net margin of --. AC Immune SA's return on equity of -37.26% beat NLS Pharmaceutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ACIU
    AC Immune SA
    -- -$0.18 $124.3M
    NLSP
    NLS Pharmaceutics
    -- -- --
  • What do Analysts Say About ACIU or NLSP?

    AC Immune SA has a consensus price target of $10.08, signalling upside risk potential of 340.11%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 15089.87%. Given that NLS Pharmaceutics has higher upside potential than AC Immune SA, analysts believe NLS Pharmaceutics is more attractive than AC Immune SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACIU
    AC Immune SA
    3 0 0
    NLSP
    NLS Pharmaceutics
    0 0 0
  • Is ACIU or NLSP More Risky?

    AC Immune SA has a beta of 1.226, which suggesting that the stock is 22.632% more volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ACIU or NLSP?

    AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACIU or NLSP?

    AC Immune SA quarterly revenues are $1.3M, which are larger than NLS Pharmaceutics quarterly revenues of --. AC Immune SA's net income of -$18M is higher than NLS Pharmaceutics's net income of --. Notably, AC Immune SA's price-to-earnings ratio is -- while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is -- versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACIU
    AC Immune SA
    -- -- $1.3M -$18M
    NLSP
    NLS Pharmaceutics
    -- -- -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Reddit a Buy on the Dip?
Is Reddit a Buy on the Dip?

Reddit (NYSE:RDDT) share price has been on the proverbial ropes…

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock